Y 39983

Drug Profile

Y 39983

Alternative Names: RKI-983; SNJ-1656; Y39983

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Senju Pharmaceutical
  • Class Antiglaucomas; Eye disorder therapies; Pyridines; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glaucoma; Ocular hypertension

Most Recent Events

  • 30 Oct 2008 Phase-II clinical trials in Glaucoma in Japan (Ophthalmic)
  • 05 Feb 2008 Y 39983 is still in phase I trials for Glaucoma in Japan
  • 23 Nov 2005 Senju Pharmaceutical has signed a global development and commercialisation agreement with Novartis, excluding Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top